Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Lannett Company Dropped Over 14% Today

By Maxx Chatsko - Nov 9, 2018 at 1:33PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors sent shares soaring yesterday, but the future is still chock full of uncertainty for the generic drug distributor.

What happened

Shares of Lannett Company (LCI -3.35%) fell over 14% today after rising 36.5% yesterday on an upbeat fiscal first-quarter 2019 operational update. Investors have become accustomed to extreme volatility following the August 2018 announcement that the generic drug manufacturer would lose its single most important customer -- responsible for $253 million, or 37%, of total revenue in fiscal 2018 -- in March 2019.

Yesterday's stock pop was driven by the optimistic tone struck by Lannett Company that it was well prepared to survive the lost contract in fiscal 2019 and beyond. Today's decline is simply investors using the massive surge as a great time to cut their losses and exit the stock altogether.

As of 2:08 p.m. EST, the stock had settled to a 11.8% loss.

A businessman holding out his hand flat with a red bar chart showing losses hovering over it.

Image source: Getty Images.

So what

Lannett Company will lose an agreement with Jerome Stevens Pharmaceuticals (JSP) in March 2019, or right around the end of the business' fiscal third-quarter 2019, that supplied the distributor with five different products. That included the thyroid deficiency medication levothyroxine sodium, which generated $245.9 million in revenue alone in fiscal 2018. It was also one of the most important growth products in the generic drug portfolio.

Given the importance of the drug, it shouldn't be surprising that shares were absolutely clobbered on the news that JSP was running into the arms of upstart Amneal Pharmaceuticals. JSP's former fling has seen its market cap fall from over $1 billion to just $200 million as a result.

But Lannett Company laid out an ambitious plan to begin picking up the pieces. Since the beginning of 2018 (the calendar year), the generic drug company launched 16 new products that are expected to contribute $75 million in revenue during its fiscal 2019 (which ends in July 2019). Meanwhile, the business expects to reap $66 million in annual cost savings by fiscal 2020. Half of that will be reinvested in new growth opportunities. 

Now what

Should the company deliver on the goals laid out during its fiscal first-quarter 2019 operational update, then the business has a real shot at significantly blunting the blow received from the lost JSP supply contract -- eventually. The near term might be an entirely different story. Will investors be so cheery when Lannett Company reports its first full quarter (that would be the fiscal fourth-quarter of 2019) without the significant earnings contribution from levothyroxine sodium tablets? It's likely that the numbers will remind investors just how far the business has to go before it fully recovers, which promises to make this a volatile stock for the foreseeable future without any big developments.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Lannett Company, Inc. Stock Quote
Lannett Company, Inc.
LCI
$0.58 (-3.35%) $0.02

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
336%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 06/25/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.